报告地点：Hanover Auditorium - Hall 7.2c

报告地点（图片来自ESMO官网）

摘要号：2095MO

研究名称（英文）：Pembrolizumab and trastuzumab in combination with FLPembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive localized esophagogastric adenocarcinoma: Interim analysis of the phase II PHERFLOT/IKF-053 trial of the AIO study group (AIO STO 0321)OT in the perioperative treatment of HER2-positive localized esophagogastric adenocarcinoma: Interim analysis of the phase II PHERFLOT/IKF-053 trial of the AIO study group (AIO STO 0321)

讲者：Joseph Tintelnot (Hamburg, Germany)

当地时间：2025/10/18 | 10:15 - 10:20

北京时间：2025/10/18 | 16:15 - 16:20

摘要号：LBA82

研究名称（英文）：Tislelizumab combined with induction chemotherapy and concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma: a multicenter, randomized, phase II trial (EC-CRT-002)

讲者：习勉 | 中山大学肿瘤防治中心

当地时间：2025/10/18 | 10:20 - 10:25

北京时间：2025/10/18 | 16:20 - 16:25

摘要号：2112MO

研究名称（英文）：Domvanalimab (dom), zimberelimab (zim), and FOLFOX in first-line (1L) advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma (GC/GEJC/EAC): 26-month update from EDGE-Gastric, arm A1

讲者：Yelena Y. Janjigian (New York, United States of America, NY)

当地时间：2025/10/18 | 10:25 - 10:30

北京时间：2025/10/18 | 16:25 - 16:30

摘要号：2096MO

研究名称（英文）：Systemic therapy, gastrectomy and CRS/HIPEC vs systemic therapy alone for gastric cancer with limited peritoneal dissemination: Results of the randomised PERISCOPE II trial

讲者：Judith S. Quik (Amsterdam, Netherlands)

当地时间：2025/10/18 | 10:45 - 10:50

北京时间：2025/10/18 | 16:45 - 16:50

摘要号：LBA83

研究名称（英文）：RC118 (CLDN18.2-targeted ADC) combined with PD-1 blockade or RC148 (PD-1/VEGF bispecific antibody) for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (la/m G/GEJA)

讲者：刘天舒 | 复旦大学附属中山医院

当地时间：2025/10/18 | 10:55 - 11:00

北京时间：2025/10/18 | 16:55 - 17:00